INDRAPRASTHA MEDICAL CORP
INDRAMEDCO · Pharma · NSE
₹406
Current Market Price
Fair Value (DCF)
₹649
Margin of Safety
+59.7%
Updated just now
YieldIQ Score
86/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
76%
ROE
—
Debt/Equity
0.05
WACC
9.7%
Market Cap
₹3,726 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
32.6%
Return on capital employed
EV / EBITDA
12.3×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
72.4×
EBIT covers interest
Current Ratio
2.41×
Short-term liquidity
Asset Turnover
1.53×
Revenue per ₹ of assets
Revenue CAGR (3Y)
14.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹406.45
Bear case
₹349.78
MoS -16.2%
Base case
₹649.06
MoS +37.4%
Bull case
₹791.45
MoS +48.6%
Ratio Trends
INDRAMEDCO · last 8 annual periods
ROE
27.0%
ROCE
41.9%
Operating Margin
—
Debt / Equity
0.05×
PE
39.3×
EV / EBITDA
4.6×
Historical Financials
INDRAMEDCO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹613 Cr | ₹888 Cr | ₹274 Cr | ₹315 Cr | ₹1307 Cr | +20.8% |
| EBITDA | — | ₹115 Cr | ₹157 Cr | ₹207 Cr | ₹264 Cr | +23.2% |
| EBIT | ₹24.2 Cr | ₹82.5 Cr | ₹28.1 Cr | ₹43.1 Cr | — | +15.6% |
| PAT | ₹15.1 Cr | ₹58.6 Cr | ₹19.8 Cr | ₹31.2 Cr | ₹161 Cr | +80.7% |
| EPS (diluted) | ₹1.65 | ₹6.39 | ₹2.16 | ₹3.40 | — | +19.8% |
| CFO | ₹27.9 Cr | ₹71.3 Cr | ₹144 Cr | ₹200 Cr | ₹157 Cr | +54.0% |
| CapEx | — | — | — | — | ₹-36.3 Cr | — |
| FCF | — | — | — | — | ₹120 Cr | +0.0% |
| Total Assets | — | ₹462 Cr | ₹555 Cr | ₹723 Cr | ₹852 Cr | +16.5% |
| Total Debt | — | — | ₹0.0 Cr | ₹0.0 Cr | ₹32.8 Cr | — |
| Shareholders' Equity | — | — | ₹379 Cr | ₹478 Cr | ₹597 Cr | +12.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INDRAMEDCO vs 2 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SHALBY SHALBY | — | — | Pending | 0.6% | — |
| GPTHEALTH GPT HEALTHCARE LIMITED | +38.5% | 60 | Undervalued | 20.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for INDRAMEDCO in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. INDRAPRASTHA MEDICAL CORP (INDRAMEDCO.NS) trades at 406.45 vs a model fair value of 649.06, a gap of 59.7%. Piotroski F-score: 6/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of INDRAMEDCO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INDRAMEDCO →
Compare
Head-to-head with peers
Compare INDRAMEDCO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INDRAMEDCONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.